Dr Amy Thomas, a Research Associate at Bristol Medical School, has been awarded an ‘Unsung COVID Heroes’ award from WISE, an organisation that promotes women in science, maths and engineering (STEM), for her work during the COVID-19 pandemic.
The risk of blood clots after COVID-19 vaccinations is very low finds a new study of 46-million adults in England. The research, which involved University of Bristol academics, showed that people vaccinated with Oxford-AstraZeneca or Pfizer-BioNTech had a lower risk of all venous clots (such as deep vein thrombosis and pulmonary embolism) and all arterial clots (such as strokes and heart attacks), particularly in people over 70 years.
An increase in the number of non-COVID-19 respiratory infections should be expected this winter, say scientists. The warning comes following the results of a new study, published in The Lancet Regional Health – Europe, which found that over 55% of respiratory disease hospitalisations during the pandemic’s peak were caused by non-SARS-CoV-2 infections.
New research from the universities of Surrey and Bristol and ESPCI Paris has shown that FFP2 (filtering facepiece) respirator masks are five times more efficient at filtering particles which carry the Covid-19 virus than cloth masks.
An international team of scientists, led by the University of Bristol, has been investigating how the SARS-CoV-2 virus, the coronavirus responsible for the COVID-19 pandemic, manipulates host proteins to penetrate into human cells. After identifying Neuropilin-1 (NRP1) as a host factor for SARS-CoV-2 infection, new findings published in the journal of the Proceedings of the National Academy of Sciences (PNAS) today [14 June] describe how the coronavirus subverts a host cell pathway in order to infect human cells.
Antiplatelet drugs such as aspirin have little effect on the need for life support in COVID-19, but they may improve survival in the following months according to a new international study led in the UK by researchers at the University of Bristol and Imperial College London.
A new study has shown how SARS-CoV-2 may contribute to severe microvascular damage seen in severely-ill COVID-19 patients by transforming human heart vascular cells into inflammatory cells, without infecting them. The University of Bristol-led research, published in Clinical Science, indicates blocking antibodies could represent a new treatment to alleviate cardiovascular complications.
Some public venues may need better ventilation to prevent the spread of COVID-19 following growing evidence of the potential for 'long distance' airborne transmission of the disease, suggests research published by The BMJ today [29 June].
SARS-CoV-2-infected individuals could have different variants hidden in different parts of the body.
Vigorous exercise does not produce significantly more respiratory particles than speaking, but high-intensity exercise does, finds new University of Bristol-led research. The study, published in Communications Medicine, is the first to measure exhaled aerosols generated during exercise, to help inform the risk of airborne viral transmission of SARS-CoV-2 for indoor exercise facilities and sporting and physical group activities.
